Cencora, Inc. (NYSE:COR) Stake Reduced by Nicholas Hoffman & Company LLC.

Nicholas Hoffman & Company LLC. cut its stake in Cencora, Inc. (NYSE:COR) by 18.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,835 shares of the company’s stock after selling 659 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in Cencora were worth $637,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in COR. Sylvest Advisors LLC bought a new stake in shares of Cencora during the fourth quarter valued at about $1,105,000. Insight Wealth Strategies LLC increased its stake in Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after buying an additional 11,232 shares during the period. Cerity Partners LLC increased its stake in Cencora by 10.1% during the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock valued at $8,881,000 after buying an additional 3,610 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its position in shares of Cencora by 71.1% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after buying an additional 2,928 shares in the last quarter. Finally, Portfolio Design Labs LLC acquired a new stake in shares of Cencora in the 3rd quarter worth approximately $1,404,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Down 0.6 %

Shares of NYSE:COR opened at $243.03 on Tuesday. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26. The company has a market capitalization of $46.97 billion, a PE ratio of 34.57, a P/E/G ratio of 1.49 and a beta of 0.49. The company’s fifty day moving average is $238.75 and its 200-day moving average is $237.41. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts predict that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio is currently 31.29%.

Analyst Ratings Changes

COR has been the topic of several research analyst reports. Wells Fargo & Company lifted their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. UBS Group lifted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Robert W. Baird raised their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, Evercore ISI increased their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.